Orchard Therapeutics partners with Dutch CMO PharmaCell to deliver gene therapy manufacturing

The partnership is expected to advance development of Orchard's rare disease investigational drugs.

By Suzanne Elvidge • Jan. 12, 2017

Bird Rock one step closer to acquisition by J&J

The approval of a Phase 1 trial for one of the small biopharma's drugs furthers the possibility of a takeover from Johnson & Johnson, which locked down acquisition rights earlier this year.

By Suzanne Elvidge • Jan. 12, 2017

JPM: Day 3 round-up

President-elect Trump threw a wrench into biotech's momentum with comments about drug pricing and other events at the last full day of J.P. Morgan. 

By Lisa LaMotta • Jan. 11, 2017

Vertex hands off cancer drugs to Merck KGaA

The decision fits a larger industry trend of paring down pipelines and allows Vertex to focus on its cystic fibrosis products.

By Jacob Bell • Jan. 11, 2017

J&J to launch newest JLABS incubator in NYC

Armed with $17 million in state funds, Johnson & Johnson hopes to create a home for as many as 30 life science startups.

By Judy Packer-Tursman • Jan. 11, 2017

JPM: A sunny tone despite rain

Executives at a BioPharma Dive-hosted panel discussed the changing tides of M&A. 

By Lisa LaMotta • Jan. 10, 2017

Kite inks China, Japan deals ahead of possible CAR-T drug approval

Through a joint venture with China's Fosun Pharma, the CAR-T specialist gains a foothold for its lead drug candidate in the world's second biggest pharma market.

By Jacob Bell • Jan. 10, 2017

Sanofi, Immunext partner to develop autoimmune therapies

Sanofi has agreed to fork over as much as $500 million in milestone payments to develop the biotech's monoclonal antibody aimed at treating diseases such as lupus and multiple sclerosis.

By Judy Packer-Tursman • Jan. 10, 2017

Allergan partnerships with Assembly Biosciences, Lysosomal target gut bugs and CNS

The deals allow Allergan to expand its pipeline into new therapeutic areas.

By Suzanne Elvidge • Jan. 10, 2017

Celgene locks down option to buy autoimmune drugmaker

The research collaboration agreement gives Celgene — which is eager to diversify its pipeline — the exclusive rights to buy Swiss biotech Anokion.

By Suzanne Elvidge • Jan. 10, 2017

JPM: Valeant sells off Dendreon, skincare brands for $2.1B

Trapped by debt built up under its former 'acquire-and-hike' business strategy, Valeant has been looking to slim down in exchange for some much-needed cash.

By Ned Pagliarulo • Jan. 10, 2017

JPM: Day 1 round-up

The first day of the J.P. Morgan Healthcare Conference started off with a bang as several companies announced deals. 

By Lisa LaMotta • Jan. 9, 2017

Pharma M&A may see 'banner year' in 2017, EY predicts

Consultancy EY anticipates higher pricing pressure and formidable firepower should spur an uptick in M&A over the next year, according to its newly released report.

By Jacob Bell • Jan. 9, 2017

Savara expands pipeline in reverse merger with Mast

Mast began searching for potential partners after shuttering its lead program in the wake of a Phase 3 miss last September.

By Judy Packer-Tursman • Jan. 9, 2017

JPM: Takeda acquires Ariad in $5.2B deal

Takeda has been on the hunt for acquisition targets in the U.S. Ariad fits the bill, but comes with perhaps unwanted scrutiny over the price tag for its main drug. 

By Jacob Bell • Jan. 9, 2017

Novartis hooks up with Ionis for access to CV drugs

Novartis now has the option to boost its cardiometabolic offerings in a deal that could be worth more than $1.6 billion.

By Suzanne Elvidge • Jan. 9, 2017

JPM: Illumina links up with IBM's Watson

The partnership aims to speed the analysis and interpretation of sequencing data created by one of Illumina's tumor profiling panels. 

By Suzanne Elvidge • Jan. 9, 2017

JPM: Ipsen snatches up Merrimack's Onivyde for $575M

Selling its crown jewel, Merrimack will substantially cut its workforce and pivot from commercialization efforts to a new focus on three pipeline assets. 

By Ned Pagliarulo • Jan. 8, 2017

Prescribed Reading: Quiet before the storm

M&A was slow in 2016 and 2017 is off to a slow start. But the JP Morgan conference in San Francisco next week could put dealmaking back in full swing. 

By Lisa LaMotta • Jan. 6, 2017

Tiny startup hooks Takeda in celiac deal

PvP Biologics will get some much-needed cash to fund preclinical work on a therapeutic for celiac disease. 

By Suzanne Elvidge • Jan. 5, 2017

Diet no more: Arena sheds Belviq in Eisai sale

The beleaguered biotech will no longer be weighed down by its failing weight loss drug, getting much-needed cash in a divestment. 

By Lisa LaMotta • Jan. 5, 2017

AstraZeneca taps APT in latest deal

An antithrombotic deal plugs a gap in AstraZeneca's CV pipeline.

By Suzanne Elvidge • Jan. 5, 2017

Is Gilead poised for deal-making?

The big biotech has made a new hire that could mean it is looking to expand its oncology presence in a big way. 

By Lisa LaMotta • Jan. 4, 2017

Tiny Rana makes a play for mRNA with Shire deal

Shire sold rights to its messenger RNA platform in exchange for an equity stake in Cambridge-based Rana Therapeutics. 

By Ned Pagliarulo • Jan. 4, 2017

RedHill, Concordia team up to market IBS drug

Under terms of a new agreement, RedHill will gain some U.S. promotional rights to Concordia's Donnatal.

By Jacob Bell • Jan. 3, 2017